{"id":41219,"date":"2026-07-22T01:15:00","date_gmt":"2026-07-21T23:15:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=07f385a42f0472b22283dae241b32b91"},"modified":"2026-07-22T01:15:00","modified_gmt":"2026-07-21T23:15:00","slug":"n-zyme-biomedical-closes-us4-6-million-series-a-financing-to-advance-clinical-development","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=41219","title":{"rendered":"N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development"},"content":{"rendered":"

\nUS$4.6 million financing fully capitalizes N-Zyme Biomedical\u2019s planned Phase 2 clinical programs in laryngopharyngeal reflux and PPI-refractory GERD, supporting the advancement of its first-in-class pepsin-targeted therapeutic approach.<\/i><\/p><\/a><\/a><\/a><\/a>

NEWARK, Del. & WAUWATOSA, Wis.--(BUSINESS WIRE)--#Biotech<\/a>--N-Zyme Biomedical<\/a> today announced the successful closing of its Series A financing, raising approximately US$4.6 million<\/b> to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for reflux disease.<\/p>

\nThe financing marks a significant milestone for the company and provides the capital to advance the clinical development of its lead therapeutic candidate across Phase 2 clinical programs for laryngopharyngeal reflux (LPR) and proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), positioning N-Zyme to further evaluate its novel pepsin inhibitor platform across multiple high-need reflux indications.<\/p>

\nThe financing was backed by a diverse group of investors, including healthcare professionals, entrepreneurs, a venture capital group, and strategic investors who recognize the significant unmet medical need in reflux disease and the potential of N-Zyme\u2019s differentiated scientific approach.<\/p>

\n\u201cWe are incredibly grateful for the confidence and support our investors have placed in N-Zyme,\u201d said Franco Vigile<\/b><\/a>, Co-Founder and Chief Executive Officer of N-Zyme Biomedical.<\/p>

\n\u201cClosing our Series A financing is more than a funding milestone\u2014it\u2019s an important validation of our science, our strategy, and our team\u2019s commitment to transforming the treatment of reflux disease. We are deeply grateful to our shareholders for believing in our vision and supporting our mission.<\/p>

\nTheir investment enables us to accelerate our Phase 2 clinical programs and brings us one step closer to delivering a first-in-class therapy for the millions of patients worldwide who continue to live with significant unmet medical needs. We believe this financing marks the beginning of an exciting new chapter for N-Zyme as we continue building a leading biotechnology company dedicated to improving the lives of patients with reflux disease.\u201d<\/p>

\nDr. Nikki Johnston<\/b><\/a>, Co-Founder and Chief Scientific Officer of N-Zyme Biomedical, added, \u201cThis financing provides the resources necessary to continue rigorously evaluating our novel therapeutic approach through well-designed clinical studies. We remain committed to advancing the science and generating high-quality clinical evidence that we believe has the potential to meaningfully improve the lives of patients living with reflux disease. We are excited to build on the strong momentum we\u2019ve established and continue advancing a therapeutic platform that has the potential to redefine the treatment paradigm for reflux disease.\u201d<\/p>

\nUnlike conventional therapies that primarily reduce gastric acid production, N-Zyme\u2019s investigational therapy is designed to inhibit pepsin\u2014the digestive enzyme increasingly recognized as a key driver of tissue damage and persistent symptoms in reflux disease. By targeting this underlying mechanism, the company believes its approach has the potential to redefine the treatment paradigm for reflux disease.<\/p>

\nProceeds from the financing will support the continued advancement of the company\u2019s Phase 2 clinical programs, including the ongoing Phase 2 evaluation of its lead therapeutic candidate for LPR and planned Phase 2 development in patients with PPI-refractory GERD, as well as regulatory and manufacturing activities, expansion of scientific and business development initiatives, and general corporate purposes.<\/p>

\nThe successful financing follows a period of significant momentum for N-Zyme, including the launch of its Phase 2 clinical program for LPR, continued expansion of its global intellectual property portfolio, and growing recognition from investors, clinicians, and strategic partners.<\/p>

\nWith this financing complete, N-Zyme is well positioned to execute its next phase of growth, including advancing its Phase 2 clinical program, expanding strategic partnerships, and continuing to build a leading biotechnology company focused on improving outcomes for patients living with reflux disease.<\/p>

\nAbout N-Zyme Biomedical<\/b><\/p>

\nN-Zyme Biomedical<\/a> is a clinical-stage biotechnology company developing first-in-class therapies targeting pepsin, a key driver of tissue damage in reflux disease. The company\u2019s lead program is currently being evaluated in Phase 2 clinical trials for laryngopharyngeal reflux (LPR), with additional development planned for patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). Through its differentiated mechanism of action, N-Zyme aims to transform the treatment paradigm for reflux disease by addressing one of its underlying causes rather than simply reducing gastric acid.<\/p> Contacts<\/b>

\nMedia Contact<\/b>Franco Vigile<\/b>Co-Founder & Chief Executive Officer\nN-Zyme Biomedical\nFranco.vigile@nzymebio.com<\/a>www.nzymebio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

US$4.6 million financing fully capitalizes N-Zyme Biomedical\u2019s planned Phase 2 clinical programs in laryngopharyngeal reflux and PPI-refractory GERD, supporting the advancement of its first-in-class pepsin-targeted therapeutic approach.NEWARK, Del. & …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-41219","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/41219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41219"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/41219\/revisions"}],"predecessor-version":[{"id":41220,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/41219\/revisions\/41220"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}